New combo attack on early lung cancer shows promise
NCT ID NCT04716946
Summary
This study is testing whether adding an immunotherapy drug called durvalumab to a precise form of radiation therapy (SBRT) works better than radiation alone for early-stage lung cancer. It is for patients with a higher risk of their cancer returning who are not candidates for surgery. The main goal is to see if this combination helps keep the cancer from growing or spreading for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baptist Alliance - McI
Miami, Florida, 33143, United States
-
Hartford Healthcare (Data Collection)
Hartford, Connecticut, 06102, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk - Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Rockville Centre, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.